In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The price of Myriad Genetics, Inc (NASDAQ: MYGN) closed at $7.95 in the last session, down -5.92% from day before closing price of $8.45. In other words, the price has decreased by -$5.92 from its previous closing price. On the day, 0.9 million shares were traded. MYGN stock price reached its highest trading level at $8.438 during the session, while it also had its lowest trading level at $7.7.
Ratios:
We take a closer look at MYGN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.65 and its Current Ratio is at 1.82. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
On March 12, 2025, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $11.50 to $12.50.
On February 12, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $29.Craig Hallum initiated its Buy rating on February 12, 2025, with a $29 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 732762624 and an Enterprise Value of 780242688. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.87 while its Price-to-Book (P/B) ratio in mrq is 1.04. Its current Enterprise Value per Revenue stands at 0.932 whereas that against EBITDA is -29.114.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.99, which has changed by -0.5933504 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $7.35. The 50-Day Moving Average of the stock is -27.42%, while the 200-Day Moving Average is calculated to be -58.14%.
Shares Statistics:
According to the various share statistics, MYGN traded on average about 1.13M shares per day over the past 3-months and 1094280 shares per day over the past 10 days. A total of 91.30M shares are outstanding, with a floating share count of 87.31M. Insiders hold about 4.38% of the company’s shares, while institutions hold 101.74% stake in the company. Shares short for MYGN as of 1741910400 were 5092357 with a Short Ratio of 4.76, compared to 1739491200 on 5430019. Therefore, it implies a Short% of Shares Outstanding of 5092357 and a Short% of Float of 7.79.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
